

◆ Department of Continuing Medical Education ◆

**Conflict of Interest Disclosure and Resolution & Core Competencies  
2026 California Head & Neck Cancer Consortium  
June 13, 2026**

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all CME-Accredited faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships<sup>1</sup> with any ineligible company<sup>2</sup>. To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. All relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

**CORE COMPETENCIES**

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below.

<b>Conference Faculty</b>	<b>Commercial Interest</b>	<b>Conflict/ Resolution &amp; Faculty Discussion of Off-Label Drugs</b>	<b>Core Competencies</b>
Ehab Hanna, MD	I do not have any relevant financial relationships with ineligible companies.	None	1, 2 & 4
Juan C. Hernandez-Prera, MD	I do not have any relevant financial relationships with ineligible companies.	None	1, 2, 3, 4 & 5
Luke Ledbetter, MD	I do not have any relevant financial relationships with ineligible companies.	None	3 & 4
Daneng Li, MD	I do not have any relevant financial relationships with ineligible companies.	None	Reviewer
Ellie Maghami, MD	I do not have any relevant financial relationships with ineligible companies.	None	Planner Moderator
Crystal Saavedra, BA	I do not have any relevant financial relationships with ineligible companies.	None	Planner
Sagus Sampath, MD	I do not have any relevant financial relationships with ineligible companies.	None	Planner 1, 2, 3, 4, 5 & 6
Aditya Shreenivas, MD, MS	Grant/Research Support from Caris Life Sciences and Foundation Medicine; Consultant for Bayer, Fennec Pharmaceuticals, Fulgent, Lilly and Merus.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.  <i>Off-label/Investigational use of: Enasidenib and Tazemetostat</i>	Planner 1, 2, 3, 4, 5 & 6

1. The ACCME defines “relevant” financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.  
2. The ACCME defines an “ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.